Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoidosis | 4 | 2020 | 77 | 2.090 |
Why?
|
| Enterotoxins | 4 | 2021 | 40 | 1.140 |
Why?
|
| Biomarkers | 2 | 2020 | 1593 | 0.960 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 92 | 0.950 |
Why?
|
| Hot Temperature | 1 | 2021 | 152 | 0.740 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 37 | 0.730 |
Why?
|
| B-Lymphocytes | 4 | 2020 | 329 | 0.690 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 179 | 0.690 |
Why?
|
| Cholera Toxin | 2 | 2007 | 30 | 0.540 |
Why?
|
| Transcription Factor RelA | 2 | 2011 | 47 | 0.470 |
Why?
|
| Plasma Cells | 3 | 2022 | 19 | 0.390 |
Why?
|
| Lymphocyte Subsets | 1 | 2011 | 16 | 0.390 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2010 | 226 | 0.390 |
Why?
|
| Bacterial Toxins | 3 | 2006 | 50 | 0.380 |
Why?
|
| CD40 Ligand | 2 | 2010 | 14 | 0.380 |
Why?
|
| Clonal Anergy | 1 | 2010 | 4 | 0.380 |
Why?
|
| Immunity, Humoral | 1 | 2011 | 42 | 0.380 |
Why?
|
| Escherichia coli Proteins | 3 | 2006 | 65 | 0.380 |
Why?
|
| Interferon-gamma | 2 | 2010 | 241 | 0.350 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1851 | 0.280 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2007 | 41 | 0.280 |
Why?
|
| Immunoglobulin A | 1 | 2007 | 79 | 0.280 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 172 | 0.270 |
Why?
|
| Up-Regulation | 2 | 2009 | 682 | 0.250 |
Why?
|
| Prognosis | 2 | 2020 | 2093 | 0.250 |
Why?
|
| Cytokines | 3 | 2020 | 866 | 0.240 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 244 | 0.240 |
Why?
|
| Lymphocytes | 1 | 2005 | 228 | 0.240 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 248 | 0.230 |
Why?
|
| Protective Factors | 1 | 2022 | 24 | 0.210 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2022 | 5 | 0.200 |
Why?
|
| Antibody Formation | 2 | 2021 | 93 | 0.200 |
Why?
|
| Bortezomib | 1 | 2022 | 45 | 0.200 |
Why?
|
| Lymphocyte Count | 2 | 2020 | 53 | 0.200 |
Why?
|
| Precancerous Conditions | 1 | 2022 | 74 | 0.200 |
Why?
|
| Bone Marrow | 1 | 2022 | 168 | 0.190 |
Why?
|
| Acinetobacter Infections | 1 | 2021 | 5 | 0.190 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2021 | 15 | 0.190 |
Why?
|
| Acinetobacter baumannii | 1 | 2021 | 22 | 0.190 |
Why?
|
| Hexosaminidases | 1 | 2020 | 7 | 0.190 |
Why?
|
| Plasma Exchange | 1 | 2020 | 18 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 213 | 0.180 |
Why?
|
| Immunologic Factors | 1 | 2021 | 87 | 0.180 |
Why?
|
| Serum Amyloid A Protein | 1 | 2020 | 33 | 0.180 |
Why?
|
| Autophagy | 1 | 2022 | 208 | 0.180 |
Why?
|
| Mycobacterium | 1 | 2020 | 12 | 0.180 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 126 | 0.170 |
Why?
|
| Humans | 10 | 2022 | 68618 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2021 | 215 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 5 | 2007 | 532 | 0.170 |
Why?
|
| Apoptosis | 2 | 2005 | 1641 | 0.160 |
Why?
|
| Macrophages | 2 | 2020 | 647 | 0.150 |
Why?
|
| Disease Progression | 1 | 2020 | 1038 | 0.140 |
Why?
|
| Gangliosides | 2 | 2006 | 29 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 597 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 2 | 2006 | 63 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2020 | 2689 | 0.120 |
Why?
|
| Lymphocyte Activation | 2 | 2007 | 397 | 0.120 |
Why?
|
| Animals | 7 | 2020 | 20881 | 0.110 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2011 | 8 | 0.100 |
Why?
|
| Lymphopenia | 1 | 2011 | 12 | 0.100 |
Why?
|
| Immunoglobulin D | 1 | 2011 | 14 | 0.100 |
Why?
|
| Antigens, CD19 | 1 | 2011 | 17 | 0.100 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2010 | 27 | 0.090 |
Why?
|
| Immunologic Memory | 1 | 2011 | 75 | 0.090 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 39 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2010 | 230 | 0.090 |
Why?
|
| Mice | 6 | 2009 | 8474 | 0.090 |
Why?
|
| Macrophages, Alveolar | 1 | 2009 | 34 | 0.080 |
Why?
|
| Escherichia coli | 3 | 2006 | 368 | 0.080 |
Why?
|
| Immunity, Mucosal | 2 | 2006 | 19 | 0.080 |
Why?
|
| Th1 Cells | 1 | 2009 | 101 | 0.080 |
Why?
|
| PPAR gamma | 1 | 2009 | 95 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 498 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2009 | 235 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2009 | 2673 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2010 | 1174 | 0.070 |
Why?
|
| Adult | 3 | 2020 | 21403 | 0.070 |
Why?
|
| Vibrio cholerae | 1 | 2005 | 6 | 0.060 |
Why?
|
| Lung | 1 | 2009 | 849 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 266 | 0.050 |
Why?
|
| Female | 5 | 2020 | 38074 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 32 | 0.050 |
Why?
|
| Biofilms | 1 | 2021 | 72 | 0.050 |
Why?
|
| Genomics | 1 | 2021 | 168 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 76 | 0.040 |
Why?
|
| Mutation | 1 | 2005 | 1213 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 190 | 0.040 |
Why?
|
| Critical Illness | 1 | 2020 | 191 | 0.040 |
Why?
|
| Middle Aged | 2 | 2020 | 21147 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 947 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 1342 | 0.030 |
Why?
|
| Streptococcus mutans | 2 | 2006 | 11 | 0.030 |
Why?
|
| Administration, Intranasal | 2 | 2006 | 88 | 0.030 |
Why?
|
| Male | 2 | 2020 | 37321 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 1026 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 3705 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2009 | 1692 | 0.030 |
Why?
|
| Cell Line | 2 | 2006 | 1752 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 2791 | 0.020 |
Why?
|
| Lentivirus | 1 | 2009 | 35 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 81 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2009 | 117 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2009 | 201 | 0.020 |
Why?
|
| Homeostasis | 1 | 2009 | 291 | 0.020 |
Why?
|
| Streptococcal Vaccines | 1 | 2006 | 2 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2006 | 10 | 0.020 |
Why?
|
| CD40 Antigens | 1 | 2006 | 9 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2006 | 23 | 0.020 |
Why?
|
| Adhesins, Bacterial | 1 | 2006 | 13 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2006 | 20 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2006 | 54 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 77 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1033 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2006 | 90 | 0.020 |
Why?
|
| Models, Animal | 1 | 2006 | 252 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 2005 | 46 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2005 | 41 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2006 | 201 | 0.020 |
Why?
|
| Immunization | 1 | 2005 | 86 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 481 | 0.010 |
Why?
|
| Interleukin-5 | 1 | 2003 | 14 | 0.010 |
Why?
|
| Protein Binding | 1 | 2006 | 1027 | 0.010 |
Why?
|
| Cell Separation | 1 | 2003 | 132 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 260 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 217 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 324 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 330 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 511 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 617 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 901 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 1293 | 0.010 |
Why?
|